- Home
- MEDP vs ELAN Comparison
MEDP vs ELAN Comparison
Compare MEDP & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MEDP | ELAN |
|---|---|---|
| Founded | 1992 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 12.7B |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MEDP | ELAN |
|---|---|---|
| Price | $416.83 | $22.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $473.17 | $27.89 |
| AVG Volume (30 Days) | 455.2K | ★ 3.7M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.98 | N/A |
| EPS | ★ 4.28 | N/A |
| Revenue | N/A | ★ $4,715,000,000.00 |
| Revenue This Year | $13.19 | $8.21 |
| Revenue Next Year | $7.75 | $5.31 |
| P/E Ratio | $98.09 | ★ N/A |
| Revenue Growth | N/A | ★ 6.22 |
| 52 Week Low | $284.10 | $9.42 |
| 52 Week High | $628.92 | $27.72 |
Technical Indicators
Market Signals| Indicator | MEDP | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 36.57 | 45.08 |
| Support Level | $382.68 | $22.17 |
| Resistance Level | $485.13 | $22.89 |
| Average True Range (ATR) | 17.47 | 0.73 |
| MACD | -10.02 | -0.04 |
| Stochastic Oscillator | 27.75 | 32.62 |
Price Performance
Historical ComparisonAbout MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.